Why is there a large gap between GAAP and adjusted EPS?

The gap ($2.98 GAAP vs. $3.28 adjusted) comes mainly from acquisition-related intangibles amortization of $165.7M pre-tax, plus acquisition deal and integration costs, restructuring expenses, and Turkey hyperinflation impact. Partially offsetting these, GAAP includes a $92.2M opioid accrual reduction, $48.2M of antitrust litigation gains, and a $48.4M LIFO credit, which are excluded from the adjusted figure. Investors should evaluate both measures, since the adjusted figure excludes recurring acquisition amortization and certain recurring items.

Was the guidance raise driven by underlying business strength or one-time items?

Management attributed the raise to strong business performance and incremental commercial COVID-19 vaccine distribution in Q1, and said previously communicated exclusive COVID-19 treatment contributions were unchanged. The raise is therefore partly tied to vaccine volumes, which may be less durable than core pharmaceutical distribution growth. The company's ex-COVID operating income growth guidance of 11–13% (up from 7–9%) suggests the core business also improved.

What is the risk from GLP-1 drugs to Cencora's margins?

GLP-1 products for diabetes and weight loss drove U.S. revenue growth but carry lower gross margins than average. This mix shift reduced U.S. segment gross margin to 2.41% from 2.46%, and consolidated adjusted gross margin fell 7 bps to 3.31%. Operating margin still expanded, but continued GLP-1 growth could keep pressuring gross margin, making the company's ability to offset this through operating expense discipline important.

How significant is the opioid settlement item and what does the prepayment mean?

In December 2023 Cencora committed to prepay the net present value of a future opioid settlement obligation, as permitted under its agreements. This led to a net $92.2M accrual reduction in Q1 that boosted GAAP operating expenses to a credit. The prepayment was made in January 2024. Accrued litigation liability fell to $4.73B from $5.06B at September 30, 2023, reflecting a lower remaining obligation, and the company's cash balance will reflect the payment in future quarters.

How strong is Cencora's balance sheet and capital return posture?

Total assets were $64.7B and total equity rose to $1.06B from $0.67B. Cash and equivalents were $2.87B, and long-term debt was $4.19B. Quarterly net debt repayments were minimal, while the company spent $385.5M on share repurchases and $105.7M on dividends. Net interest expense is guided lower for FY2024, partly due to higher interest income and the divestiture of the Egypt subsidiary. Working capital is significant, with accounts payable of $47.7B against receivables of $21.6B and inventories of $18.7B, so cash flow can swing with payables timing.

COR 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed January 31, 2024. Cited figures are marked; the original filing is the authoritative source.

Cencora, Inc. (COR) reported fiscal Q1 2024 (quarter ended December 31, 2023) results that beat expectations on the top and bottom lines and prompted a raise to full-year adjusted guidance.

Revenue rose 15.0% year-over-year to $72.3 billion^a, driven by a 15.9% increase in U.S. Healthcare Solutions, which benefited from GLP-1 drug volumes, specialty products, and COVID-19 vaccine distribution. GAAP diluted EPS was $2.98 (up 27.9%), while adjusted diluted EPS was $3.28 (up 21.0%). GAAP results were flattered by a $92.2 million net opioid litigation accrual reduction tied to a prepayment commitment, while adjusted results exclude this and other items such as acquisition amortization of $165.7 million, which is a meaningful drag on GAAP earnings.

Management raised fiscal 2024 adjusted diluted EPS guidance to $13.25^b–$13.50 from $12.70–$13.00, and lifted revenue growth guidance to 10–12% from 7–10%. Adjusted operating income growth guidance moved up to 8–10% from 4–6%, and net interest expense guidance was lowered to $185–$215 million. Cencora also declared a quarterly dividend of $0.51 per share, and cash flow from operations was $885 million for the quarter, supported by a $1.8 billion increase in accounts payable.

Investors should note that the quality of the beat is mixed. Adjusted gross margin fell 7 basis points to 3.31%^c because GLP-1 products carry lower margins, and the GAAP result benefited from a one-time opioid accrual reduction and a LIFO credit.

Share count fell 2.2%^d year-over-year on buybacks, which contributed to per-share growth. Management described the guidance raise as reflecting strong business performance and incremental COVID-19 vaccine distribution in the quarter, while its previously communicated exclusive COVID-19 treatment expectations were left unchanged.

02—Key points

Key Highlights

Revenue of $72.3B, up 15.0% YoY; U.S. Healthcare Solutions up 15.9% to $65.2B, International up 6.9% to $7.1B (8.7% constant currency).
GAAP diluted EPS of $2.98 (+27.9%) vs. adjusted diluted EPS of $3.28 (+21.0%); the GAAP figure includes a $92.2M net opioid litigation accrual reduction.
FY2024 adjusted diluted EPS guidance raised to $13.25–$13.50 from $12.70–$13.00; revenue growth guidance raised to 10–12% from 7–10%.
Adjusted operating income up 20.7% to $885.7M; adjusted operating margin expanded 6 bps to 1.23%, though adjusted gross margin contracted 7 bps to 3.31% due to GLP-1 mix.
Net interest expense guidance lowered to $185–$215M from $210–$230M; quarterly operating cash flow of $885M and adjusted free cash flow of $762.7M.
Quarterly dividend declared at $0.51 per share, payable February 26, 2024 to holders of record on February 9, 2024.
Diluted share count down 2.2% YoY to 201.8M on share repurchases ($385.5M of buybacks in the quarter).

03—Questions

Frequently Asked Questions

Why is there a large gap between GAAP and adjusted EPS?
The gap ($2.98 GAAP vs. $3.28 adjusted) comes mainly from acquisition-related intangibles amortization of $165.7M pre-tax, plus acquisition deal and integration costs, restructuring expenses, and Turkey hyperinflation impact. Partially offsetting these, GAAP includes a $92.2M opioid accrual reduction, $48.2M of antitrust litigation gains, and a $48.4M LIFO credit, which are excluded from the adjusted figure. Investors should evaluate both measures, since the adjusted figure excludes recurring acquisition amortization and certain recurring items.
Was the guidance raise driven by underlying business strength or one-time items?
Management attributed the raise to strong business performance and incremental commercial COVID-19 vaccine distribution in Q1, and said previously communicated exclusive COVID-19 treatment contributions were unchanged. The raise is therefore partly tied to vaccine volumes, which may be less durable than core pharmaceutical distribution growth. The company's ex-COVID operating income growth guidance of 11–13% (up from 7–9%) suggests the core business also improved.
What is the risk from GLP-1 drugs to Cencora's margins?
GLP-1 products for diabetes and weight loss drove U.S. revenue growth but carry lower gross margins than average. This mix shift reduced U.S. segment gross margin to 2.41% from 2.46%, and consolidated adjusted gross margin fell 7 bps to 3.31%. Operating margin still expanded, but continued GLP-1 growth could keep pressuring gross margin, making the company's ability to offset this through operating expense discipline important.
How significant is the opioid settlement item and what does the prepayment mean?
In December 2023 Cencora committed to prepay the net present value of a future opioid settlement obligation, as permitted under its agreements. This led to a net $92.2M accrual reduction in Q1 that boosted GAAP operating expenses to a credit. The prepayment was made in January 2024. Accrued litigation liability fell to $4.73B from $5.06B at September 30, 2023, reflecting a lower remaining obligation, and the company's cash balance will reflect the payment in future quarters.
How strong is Cencora's balance sheet and capital return posture?
Total assets were $64.7B and total equity rose to $1.06B from $0.67B. Cash and equivalents were $2.87B, and long-term debt was $4.19B. Quarterly net debt repayments were minimal, while the company spent $385.5M on share repurchases and $105.7M on dividends. Net interest expense is guided lower for FY2024, partly due to higher interest income and the divestiture of the Egypt subsidiary. Working capital is significant, with accounts payable of $47.7B against receivables of $21.6B and inventories of $18.7B, so cash flow can swing with payables timing.

04—Continue

← View all 8-K filings